View as webpage.

October 24, 2025

 

Welcome to the latest edition of the BioLines Weekender...


Last week, BioNJ hosted roundtable discussions with Republican gubernatorial candidate, Jack Ciattarelli, and Democratic candidate for Lt. Governor, Dr. Dale Caldwell, running mate of Congresswoman Mikie Sherrill, at Bristol Myers Squibb. Members of BioNJ's Board of Directors and Public Policy Committee, representing the full spectrum of the life sciences sector, engaged in a discussion of the current status of the industry in New Jersey along with the challenges and opportunities that the next governor’s administration will encounter in the coming months.

From competitive tax policy and strengthening our State’s position as a global life sciences leader ― to the promise of onshoring and ensuring New Jerseyans have access to the medicines they need, when they need them ― the conversation spotlighted critical issues shaping the future of New Jersey.


As a reminder, here are a few important dates:

  • October 25 - November 2: Early voting period. Every county will designate in-person early voting locations open from 10AM-8PM (Mon.-Sat.) and 10AM-6PM (Sun.) with no appointments needed.
  • October 28: Deadline to apply for a mail-in ballot by mail
  • November 4: Election Day and deadline for post office receipt of mail-in ballots


For the latest updates on the campaign, as well as other policy related issues, click here to receive BioNJ's bi-weekly Public Policy Update.


Because Patients Can't Wait®,

Debbie Hart

President and CEO

BioNJ

Upcoming BioNJ Events

calendar-white.png

BioNJ C-Suite Summit

Bridgewater Marriott

Register

October 30, 2025

BioNJ Member Café: Members Only

Virtual

Register

November 6, 2025

BioNJ Gives Back: Members Only

Register for the Insmed Location.

Register for the Sanofi Location.

December 10, 2025

BioNJ Inspiring STEM Conference

Genmab

Register

December 4, 2025

BioNJ Annual Dinner Meeting & Innovation Celebration

Hilton East Brunswick

Save the Date

February 5, 2026

 

BioNJ News

news-white.png

100% Drug Tariffs are a Dire Threat — And Patients Can't Wait

Op-ed Published in Life Science Leader

Since the start of his second term, President Trump has shown a clear commitment to improving

access to medicines for American patients. In late September 2025, his Administration reaffirmed this priority with the launch of a new direct-to-consumer prescription website — alongside the first in a series of anticipated deals with pharmaceutical manufacturers to align specific U.S. drug prices with those abroad. But these efforts came on the heels of an unprecedented move: a threat to impose a 100% tariff on select prescription drugs, aimed at driving pharmaceutical manufacturing back to the U.S. The contrast from the White House couldn’t be more stark. If enacted, tariffs of this scale could dramatically raise manufacturing costs, disrupt global supply chains, and stall critical R&D efforts. Most concerning of all, they threaten to limit access to life-saving medicines for the patients who need them most.

BioNJ to Host 13th Annual C-Suite Summit: Focus on AI, Capital Markets and Innovation in Tumultuous Times

As Featured in BINJE

BioNJ’s 13th Annual C-Suite Summit will be held on Oct. 30, at the Bridgewater Marriott, bringing together a premier lineup of executive leaders to address the most pressing strategic challenges facing the life sciences industry. The Summit will convene top executives from emerging startups, established global players, and public and private organizations to foster high-level connections and candid dialogue. The event comes as the life sciences landscape is defined by AI-powered advancements, shortened product lifecycles, economic uncertainty, and geopolitical shifts. The Summit offers substantial networking opportunities, including direct access to speakers, aiming to foster “authentic dialogue and lasting relationships among executive decision-makers and forward-thinking innovators.”

Ascendis Pharma Doubles Footprint in Princeton

As Featured in New Jersey Business Magazine

Princeton-based BioNJ Member Ascendis Pharma held a ribbon-cutting ceremony to celebrate the opening of its new and expanded office in Princeton. With this location, the company strengthens Ascendis’ presence across North America and supports its commitment to serve the unmet needs of patients with rare endocrinology conditions. The number of employees of the Ascendis U.S. business has more than doubled from 2024 to 2025. This growth includes a shift from just under 50 employees located in the Princeton office to plans for well more than 100 employees. With the new office location, Ascendis’ Princeton footprint also almost doubled. During the ceremony, Debbie Hart, President and CEO, BioNJ, spoke about the vital role Ascendis plays in New Jersey’s life sciences community — creating jobs, cultivating talent and infusing our innovation ecosystem with fresh energy and scientific excellence.

Putting Patients First:

The Value of Medical Innovation -

Recent Stories in the News

5a2d7358-0f00-4be1-be92-988ecde081c5 image

Op-Ed: Cancer is Enough of a Battle Without Insurance Roadblocks

Cancer is personal to me. My mother survived breast cancer. A close friend died of glioblastoma at just 22. And while I didn’t have cancer, I know what it’s like to be a patient fighting for your life.

In pharmacy school, I was diagnosed with severe aplastic anemia and told I might have just six months to live if untreated. I spent 23 days in a hospital bed, receiving chemotherapy and a bone marrow transplant from my younger sister. I remember the fear, confusion and total dependence on my doctors. That’s why it’s infuriating to see insurance companies sit behind computer screens and overrule physicians and health care teams, deciding which treatments cancer patients can — and cannot — receive. In my role as director of pharmacy for a large community oncology practice, I see this every day.

Maryland’s Drug Affordability Board has Been a Failure

Six years ago, Maryland made national headlines by creating the first-ever Prescription Drug Affordability Board (PDAB). It was heralded as a groundbreaking step to make prescription drugs more affordable and give families some breathing room at the pharmacy counter. But today, the results are impossible to ignore — and deeply disappointing. Despite all the promises, the PDAB hasn’t lowered a single prescription cost. Not one. Instead, it risks adding more red tape and fewer choices for the patients who need help most. The board’s main lever — the so-called upper payment limit — sounds like a fix on paper. In reality, it’s a distraction. These limits don’t touch the true reasons families struggle with medication costs: skyrocketing insurance deductibles, confusing coinsurance rules and the shadowy role of pharmacy benefit managers (PBMs) who quietly dictate what patients pay.

State Launches Strategic Innovation Center Advisory Council to Accelerate Innovation Ecosystem

Gov. Phil Murphy formally launched the Strategic Innovation Center Advisory Council (SIC-AC), a new high-level body tasked with strengthening New Jersey’s innovation ecosystem. The inaugural meeting brought together a diverse group of key stakeholders, including academic and corporate leaders, industry champions, and government officials. The SIC-AC is powered by the New Jersey Economic Development Authority (NJEDA) and is designed to advance the network of 12 Strategic Innovation Centers (SICs) established during the Murphy Administration. SICs are vital facilities — such as accelerators, incubators and research centers — that provide mentorship, networking, training and business support services to foster research, development and entrepreneurship. The council’s primary goal is to make New Jersey a national model for sustainable and equitable economic growth in the innovation sector.

The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs

The Drug Price Negotiation Program (DPNP) of the Inflation Reduction Act of 2022 (IRA) aims to reduce Medicare spending on prescription drugs by reducing prices on high-spend drugs selected each year for the DPNP. The DPNP will reduce Medicare payments for selected drugs directly but may also reduce industry revenues indirectly when nonselected drugs in the same class experience downward price pressures and other payers press for price reductions for selected and competing products. Although uncertainty about the magnitude and timing of class-wide and market spillover effects will take years to resolve, few industry observers deny that reductions in future revenue and expected returns to research and development (R&D) investments because of the DPNP will likely affect the level and mix of industry investment. 

Inflation Reduction Act Impact on Pharmaceutical Investment: Insights from Investor Interviews

The Inflation Reduction Act (IRA) significantly reshapes the landscape of drug pricing in the United States, introducing new mechanisms of government price regulation and a cap on out-of-pocket drug costs for Medicare patients. The law's impact on pharmaceutical innovation has been fiercely debated. A main concern is whether the IRA's Drug Price Negotiation Program, which directs the Centers for Medicare and Medicaid Services to set “maximum fair prices” for high-expenditure Medicare drugs, reduces manufacturers’ incentives to invest in new and ongoing drug development. It has been argued that the anticipated reduction of returns due to MFPs might: reduce the number of subsequent indications pursued, bias investment decisions away from small molecule drugs given the shorter timeline toward DPNP eligibility relative to biologic drugs, disincentivize the development of drugs with populations with heavy Medicare representation and influence the selection of the initial indication.

Bayh-Dole Coalition Shares Member Survey Responses on Secretary Lutnick’s Royalty-Sharing Proposal

The Bayh-Dole Coalition released survey results showing near-unanimous opposition to Secretary Lutnick’s royalty-sharing proposal. Respondents warned the proposal would undermine the innovation system that has powered U.S. leadership in science and technology for 45 years. The survey captures the perspectives of Bayh-Dole Coalition members from across academia, trade and advocacy associations, industry, and investment communities, who offered detailed insights into the likely consequences of requiring universities to remit a portion of patent royalties from federally-funded R&D to the federal government. All respondents stated that government royalty-sharing would not generate more taxpayer revenue than the current system, which has generated more than $1 trillion in U.S. GDP, 6.5 million jobs, 19,000 startups, and over 200 new medicines since 1996. 

Putting Americans First

America leads the world in biotechnology innovation. Yet the U.S. remains the only country where half of every dollar spent on medicine goes to middlemen and supply chain markups - rather than to patients or innovation. International price setting would devastate these American innovators, undermine investment in early stage companies, weaken U.S. competitiveness, and slow the development of lifesaving treatments — all while ignoring the true drivers of drug costs. Let's solve the real problem. Say no to international price setting - and yes to simplifying the system.

The CAR T-Cell Therapy Transformation: Understanding the Technology, Current Landscape and Future Directions

CAR T-cell therapies are the first FDA-approved medicines to leverage a patient’s own genetically modified immune cells and are winning the fight against cancer. Immunotherapy has been dubbed the latest pillar of cancer treatment. A particular type of immunotherapy, CAR T-cell therapies, usher in a new era of transformative oncology care. These therapies improve and prolong patients' lives by delivering sustained remissions where traditional therapies have failed, with the added advantage of eliminating ongoing compliance concerns through their one-time administration. What exactly has made CAR T-cell therapies so effective? What differentiates them from standard oncology treatments? What differentiates them from other immunotherapies like bispecific antibodies?

NJ Company News

news-white.png

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Bridgewater-based BioNJ Member Insmed Incorporated announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its DPP1 inhibitor BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. If approved, BRINSUPRI would be first-in-class and the first approved therapy in the European Union to treat NCFB. The CHMP opinion is based on a comprehensive scientific evaluation of the marketing authorization application, including data from the Phase 3 ASPEN and Phase 2 WILLOW studies, which were both published in the New England Journal of Medicine.

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Bridgewater-based BioNJ Member Insmed Incorporated announced that it has earned the highest ranking in Science's 2025 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the companies with the best reputations as employers. "It is an incredible privilege to see our organization recognized as the top employer in Science's annual survey for a record five consecutive years—something only achieved once before when the list first began," said Will Lewis, Chair and CEO of Insmed. "We are experiencing an extraordinary period of growth, driven by a series of clinical successes and regulatory milestones that support us in working toward our mission to transform the lives of patients with serious and rare diseases. This recognition reflects not only our deep commitment to advancing science, but also the passion and purpose that drive our work every day."

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Hopewell-based BioNJ Member BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. The decision by the FDA to grant sonrotoclax BTD and participation in Project Orbis was based on data from the BGB-11417-201 study, a Phase 1/2 study evaluating sonrotoclax in adult patients with R/R MCL, following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy.

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Princeton-based BioNJ Member Soligenix announced that its first Data Monitoring Committee (DMC) meeting for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) has concluded that there are no safety concerns with the ongoing Phase 3 study and that HyBryte™ has an acceptable safety profile that remains consistent with the safety data from all prior clinical studies. The confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) study, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent successful comparative study (protocol # HPN-CTCL-04) and an ongoing investigator-initiated study (protocol # RW-HPN-MF-01), each further supporting the design of the FLASH2 clinical trial.

Novartis Cosentyx® Meets Primary and All Secondary Endpoints in Phase III Trial in Patients With Polymyalgia Rheumatica (PMR)

East Hanover-based BioNJ Member Novartis announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx demonstrated statistically significant and clinically meaningful sustained remission vs placebo at Week 52 in adults with polymyalgia rheumatica (PMR). Full data will be presented at an upcoming medical congress and submitted to health authorities in the first half of 2026. A key secondary endpoint of the REPLENISH trial was adjusted annual cumulative steroid dose through Week 52. Other secondary measures included complete sustained remission at Week 52, and time until patients needed additional treatment

PSMAddition Data Show Novartis Pluvicto™ Delays Progression to End-Stage Prostate Cancer

East Hanover-based BioNJ Member Novartis presented new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial. Pluvicto plus standard of care (SoC) (androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI: 0.58, 0.90) versus SoC alone in patients with prostate-specific membrane antigen (PSMA)+ metastatic hormone-sensitive prostate cancer (mHSPC). Results also show an early positive trend in overall survival (OS) in patients treated with Pluvicto plus SoC (HR 0.84; 95% CI: 0.63, 1.13); follow-up will continue until data are mature.

Novartis Kisqali® 5-Year NATALEE Data Demonstrate 28% Reduction in Risk of Recurrence in the Broadest Early Breast Cancer Patient Population

East Hanover-based BioNJ Member Novartis announced results from the five-year analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months). Results showed a 28.4% reduction in risk of recurrence (HR=0.716; 95% CI 0.618-0.829; nominal p-value <0.0001) in the broadest population of patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) treated with Kisqali plus endocrine therapy (ET) compared to ET alone. The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement.

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Princeton-based BioNJ Member Bristol Myers Squibb and Orbital Therapeutics

announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo, enabling treatments that provide the precision, control, and flexibility needed to address the underlying biology and unique complexities of each disease. The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimized circular RNA encoding a CD19-targeted CAR for in vivo expression delivered via targeted lipid nanoparticles (LNPs). This in vivo approach, in which the patient’s own body serves as the manufacturer of CAR T-cells, has the potential to offer a reduced treatment burden and improved accessibility compared to ex vivo CAR T-cell therapies.

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

Princeton-based BioNJ Member Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease. Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need. Alzheimer’s disease — the most common type of dementia in adults — is a progressive, multifaceted and devastating neurodegenerative disease in which significant changes occur in the brain that cause neurons to die over time. These changes include the accumulation and spread of pathological tau, an abnormal form of the tau protein.

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients With Advanced Lung Cancer

BioNJ Member Pfizer Inc., with a site in Parsippany, announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated patients, the median OS was 22.7 months (95% CI, 14.1, 32.6), after a median follow-up of 48.2 months. The four-year OS rates were 49% (95% CI, 35, 62) and 31% (95% CI, 16, 47) for treatment-naïve and previously treated patients, respectively. These data, from pre-specified secondary trial endpoints, have been published in the Journal of Clinical Oncology.

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men With a Type of Advanced Prostate Cancer

BioNJ Member Pfizer Inc., with a site in Parsippany, and Astellas Pharma U.S. Inc. announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis. For the key secondary endpoint of OS, XTANDI plus leuprolide reduced the risk of death by 40.3% compared to leuprolide alone (Hazard Ratio [HR]: 0.597; 95% Confidence Interval [CI], 0.444-0.804; p=0.0006), making this the first and only androgen receptor inhibitor-based regimen to demonstrate an OS benefit in nmHSPC with high-risk BCR. 

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

BioNJ Member Pfizer Inc., with a site in Parsippany, announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy-based induction. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in the TUKYSA arm versus the placebo arm. Treatment with TUKYSA in combination with trastuzumab and pertuzumab was tolerable, with a safety profile generally consistent with the established safety profiles of each individual therapy. 

Chugai In-Licenses GLP-1/GIP Receptor Agonist CT-388

Berkeley Heights-based BioNJ Member Chugai Pharmaceutical Co. announced that it has concluded a license agreement with F. Hoffmann-La Roche Ltd for CT-388, a long-acting GLP-1/GIP receptor agonist, currently in development for obesity and type 2 diabetes. Under the license agreement between Roche and Chugai, Chugai obtained exclusive rights for the development and marketing of CT-388 in Japan. Roche will receive an upfront fee and milestone payments. In the overseas Phase I clinical study (CT-388-101 trial) of CT-388, adults with obesity received weekly subcutaneous injections of CT-388 for 24 weeks, resulting in a placebo-adjusted mean weigh reduction of -18.8% (p&lt;0.001) at week 24, demonstrating clinically meaningful and statistically significant weight reduction compared to placebo. In the CT-388 treatment group, 100% of participants achieved &gt;5% weight reduction, 85% achieved &gt;10%, 70% achieved &gt;15%, and 45% achieved &gt;20% weight reduction.

Chugai’s PiaSky Launched as Taiwan’s First Approved Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Berkeley Heights-based BioNJ Member Chugai Pharmaceutical Co. announced that Chugai Pharma Taiwan Ltd. (CPT), a wholly-owned subsidiary of Chugai, has launched PiaSky®, a drug created by Chugai, on October 1 for “the treatment of the patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg” as the first subcutaneous treatment in Taiwan. PiaSky is the first subcutaneous treatment approved in Taiwan for untreated and previously treated patients with C5 inhibitors. In Taiwan, PNH is classified as a rare disease, and PiaSky was designated as an orphan drug by the Ministry of Health and Welfare (MoHW) on April 24, 2025 and obtained an orphan drug import drug license from the Taiwan Food and Drug Administration (TFDA) on May 19, 2025.

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

BioNJ Member, AbbVie, with a site in Madison, announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (RINVOQ®) 15 mg, once daily, compared to adalimumab (HUMIRA®) 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis (RA) on a stable background of methotrexate (MTX) who had an inadequate response or intolerance to a TNF inhibitor (TNFi) other than adalimumab.1 This study achieved the primary endpoint and the majority of ranked secondary endpoints at week 12 with no new safety risks identified. A significantly higher proportion of patients who received upadacitinib achieved low disease activity (defined as Disease Activity Score 28 C-reactive Protein [DAS28-CRP]≤3.2; primary endpoint) and remission (defined as DAS28-CRP<2.6; ranked secondary endpoint) compared to adalimumab at week 12.

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

BioNJ Member, AbbVie, with a site in Madison, announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). Previously, RINVOQ was indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. The updated indication statement also allows the use of RINVOQ for patients after they have received at least one approved systemic therapy in the event TNF blockers are clinically inadvisable. 

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living With Bipolar I Disorder

Parsippany-based BioNJ Member Teva Pharmaceuticals and Medincell, announced that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of risperidone formulations already approved for BD-I. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose. 

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Parsippany-based BioNJ Member Teva Pharmaceuticals entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets. Tuznue® is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission (EC) marketing authorization for Tuznue® in September 2024. Under the terms of the license and supply agreement, Teva secured rights to market and distribute Tuznue® in a majority of European markets, leveraging its extensive commercial network and proven expertise in biosimilars. Prestige Biopharma will be responsible for production and supply through its EU-GMP-certified, high-tech facilities equipped with advanced single-use technology.

Novo Nordisk to Acquire Akero Therapeutics and its Promising Phase 3 FGF21 Analogue to Expand MASH Portfolio

Plainsboro-based BioNJ Member Novo Nordisk announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc., a clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in Phase 3 development for the treatment of patients with moderate to advanced liver fibrosis (F2-F3) and patients with cirrhosis (F4). The acquisition reflects Novo Nordisk’s long-term strategy to develop innovative and differentiated medicines and treat millions of more people living with diabetes, obesity and their associated comorbidities. With more than 40% of MASH patients also having type 2 diabetes, and over 80% of MASH patients being overweight or living with obesity, MASH is closely linked with Novo Nordisk’s expertise in diabetes and obesity.

GSK Announces Positive Pivotal Phase III Data for Next-Generation Low Carbon Version of Ventolin (salbutamol) Metered Dose Inhaler

Warren-based BioNJ Member GSK plc announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation of salbutamol MDI containing an innovative low carbon propellant HFA-152a shows therapeutic equivalence and is comparable in safety to salbutamol MDI containing the current propellant, HFA-134a. The findings will support regulatory submissions for the next-generation version, with launch expected from 2026, an important advance to bringing a more sustainable option to patients with respiratory disease. Nearly half a billion people are affected by asthma and chronic obstructive pulmonary disease (COPD) around the world4 and approximately 300 million salbutamol MDIs are sold globally every year. Used during an exacerbation, or “attack”, salbutamol in an MDI can help by immediately treating a sudden onset of respiratory symptoms, such as breathlessness.

Positive PIVOT-PO Phase III Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients With Complicated Urinary Tract Infections (cUTIs)

Warren-based BioNJ Member GSK plc announced full results of the positive pivotal phase III PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis (NCT06059846). Complicated UTIs represent an important health issue, with an estimated 2.9 million cases treated annually in the US alone. These infections are often caused by multidrug-resistant pathogens and carry serious risks including organ failure, sepsis, and even death. They also result in significant emergency department visits and hospitalizations, contributing to over $6 billion per year in healthcare costs.6 Current standard of care includes carbapenem antibiotics in cases of sepsis or resistance to other antibiotics but they are only available for intravenous administration typically occurring in hospital setting.

GSK’s Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

Warren-based BioNJ Member GSK plc announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to support the approval of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) in a prefilled syringe. Currently, the vaccine presentation consists of two vials, a lyophilised powder antigen and a liquid adjuvant, which are combined prior to administration. After approval by the European Commission, expected in December 2025, the new prefilled syringe will remove the need to reconstitute separate vials, simplifying the vaccine administration process for healthcare professionals. GSK’s shingles vaccine has been approved in the European Union for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 50 years or older since 2018; and in adults 18 years or older at increased risk of HZ, since 2020. GSK’s RZV is specifically designed to enhance the varicella-zoster virus (VZV) specific immune response of a declining or compromised immune system.

GSK’s Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and Over Who Are at Increased Risk Due to Immunodeficiency or Immunosuppression

Warren-based BioNJ Member GSK plc announced that the China National Medical Products Administration (NMPA) has approved Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Shingles poses a significant health burden, with approximately six million cases per year in China. Besides advancing age, other factors can increase the risk of developing shingles, including immunodeficiency or immunosuppression with no other shingles vaccine approved for this population in China. Shingles-associated pain is often described as aching, burning, stabbing or shock-like and can have a considerable impact on patients’ quality of life, e.g. affecting sleep, and ability to undertake activities of daily living including work. 

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

BioNJ Member Gilead Sciences, Inc., with a site in Morris Plains, shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. ASCENT-03 successfully met its primary endpoint of PFS with a 38% reduced risk of disease progression or death for Trodelvy versus chemotherapy (HR: 0.62; p<0.0001). Median PFS with Trodelvy was 9.7 months versus 6.9 months for chemotherapy. The PFS results for Trodelvy versus chemotherapy were consistent across prespecified subgroups, including among patients with poorer prognosis (such as those whose cancer recurred less than one year after treatment in the curative setting) and regardless of chemotherapy chosen.

Sanofi’s Efdoralprin Alfa Met All Primary and Key Secondary Endpoints in Alpha-1 Antitrypsin Deficiency Emphysema Phase 2 Study

Morristown-based BioNJ Member Sanofi announced positive results from the global ElevAATe Phase 2 study (clinical study identifier: NCT05856331) showed that efdoralprin alfa (SAR447537, formerly known as INBRX-101), met all primary and key secondary endpoints when dosed every three weeks (Q3W) or four weeks (Q4W) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema, a rare disease. Efdoralprin alfa is an investigational recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein. It demonstrated a statistically significant greater mean increase in functional AAT levels within normal range as measured by trough concentrations at steady state compared to those receiving weekly plasma-derived augmentation therapy at week 32 [p<0.0001]. The study also met key secondary endpoints, demonstrating superior mean increase in fAAT average concentration as well as higher percentage of days above the lower limit of the normal range for both Q3W and Q4W dosing.

Sanofi’s High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Morristown-based BioNJ Member Sanofi announced new data from the FLUNITY-HD study, published in The Lancet, demonstrated that Sanofi's Efluelda (known as Fluzone High-Dose in North America) significantly reduced the risk of hospitalization in adults 65 years and older compared to standard-dose influenza vaccines. The FLUNITY-HD study, unparalleled in its design and scale, harnesses the power and scientific rigor of individual randomization in real-world settings,” shared Professor Tor Biering-Sørensen, Cardiologist, Chief Investigator, and sponsor of the FLUNITY-HD study. “This first-of-its-kind study assessed the benefits of the high-dose influenza vaccine against severe outcomes compared to standard-dose, including against cardio-respiratory hospitalizations, in a randomized setting, covering two geographic areas. The results provide critical evidence, potentially reshaping public health strategies and clinical guidelines."

Sanofi’s Tzield Accepted for Expedited Review in the U.S. for Stage 3 Type 1 Diabetes Through FDA Commissioner's National Priority Voucher Pilot Program

Morristown-based BioNJ Member Sanofi announced the U.S. Food and Drug Administration (FDA) has accepted for expedited review the supplemental biologics license application (sBLA) for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes (T1D) in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D. The FDA nominated Tzield for the Commissioner's National Priority Voucher (CNPV) pilot program based on its potential to address a large unmet medical need. The CNPV program aims to shorten the review process from what normally takes 10-12 months to 1-2 months, while maintaining FDA's rigorous safety and efficacy standards. The sBLA is supported by the results from the PROTECT Phase 3 study, which met its primary endpoint, evaluating preservation of beta cell function as assessed by significantly slowing the decrease in mean C-peptide levels (area under the curve [AUC] after a four-hour mixed meal tolerance test) at trial study completion, compared to placebo.

AlphaMedixTM (212Pb-DOTAMTATE) Achieved All Primary Efficacy Endpoints in Phase 2 Study, Demonstrating Clinically Meaningful Benefits in Patients With Gastroenteropancreatic Neuroendocrine Tumors

Morristown-based BioNJ Member Sanofi announced positive results from the ALPHAMEDIX-02 Phase 2 study (clinical study identifier: NCT05153772) showed AlphaMedixTM (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR)-Targeted Alpha Therapy using the lead-212 isotope, met all primary efficacy endpoints and showed clinically meaningful overall response rates (ORR) and prolonged clinical benefits in both peptide receptor radionuclide therapy (PRRT)-naïve and PRRT-exposed patients with unresectable or metastatic SSTR positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Benefits in key secondary endpoints, including progression-free survival (PFS) and overall survival (OS), were also observed across both cohorts. AlphaMedix™ had a manageable safety profile that was similar across both cohorts. Alpha-emitters are being studied to determine their relative potency and targeted tumor activity compared to current approved therapies.

Sanofi’s Wayrilz Recommended for EU Approval by the CHMP to Treat Immune Thrombocytopenia

Morristown-based BioNJ Member Sanofi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Wayrilz (rilzabrutinib) as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. A final decision is expected in the coming months. The positive CHMP opinion is based on the pivotal LUNA 3 Phase 3 study (clinical study identifier: NCT04562766. Wayrilz met both the primary and secondary endpoints, making LUNA 3 the first Phase 3 study to show a positive impact on sustained platelet counts, bleeding, and other ITP symptoms with an oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor.

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) With a High Risk of Recurrence After Surgery and Radiation

BioNJ Member Regeneron Pharmaceuticals, Inc., with a site in Basking Ridge, announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026. The FDA approval is based on data from the pivotal Phase 3 C-POST trial investigating adjuvant Libtayo versus placebo in patients with CSCC at high risk of recurrence after surgery and radiation.

DB-OTO Results in The New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children With Profound Genetic Hearing Loss

BioNJ Member Regeneron Pharmaceuticals, Inc., with a site in Basking Ridge, announced updated data for their investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were published in The New England Journal of Medicine. These latest results from the pivotal CHORD trial show 11 out of 12 participants have experienced clinically meaningful hearing improvements, including 3 who achieved normal hearing levels. Additionally, eight participants with longer follow-up showed stability or continued improvement in their hearing, and among three who completed speech assessments, all showed significant improvement. The CHORD trial evaluated pediatric participants with profound hearing loss due to variants of the OTOF gene that received a single administration of DB-OTO via intracochlear infusion. 

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

BioNJ Member Regeneron Pharmaceuticals, Inc., with a site in Basking Ridge, announced new and updated data from its advancing oncology pipeline. Highlights include new Phase 3 C-POST data on an every 6-week dosing regimen for the PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence. The new safety and pharmacokinetic data from C-POST showcase a patient-centric approach to dosing. Patients received either adjuvant therapy with Libtayo or placebo intravenously, starting with 350 mg every 3 weeks for 12 weeks. The majority of patients were switched to every 6-week dosing after the initial 12 weeks, and the remaining patients continued with dosing every 3 weeks throughout the trial.

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Nutley-based BioNJ Member Eisai and BioNJ Member, Biogen announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category. TIME’s annual list of the Best Inventions features 300 extraordinary innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as health care and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition and impact.

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination With Padcev® (enfortumab vedotin-ejfv), for Certain Patients With Muscle-Invasive Bladder Cancer

Rahway-based BioNJ Member Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev® (enfortumab vedotin-ejfv), for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of April 7, 2026, marking the first concurrent review of both KEYTRUDA and KEYTRUDA QLEX for the same novel indication. The sBLAs are based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in collaboration with Pfizer and Astellas.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Rahway-based BioNJ Member Merck & Co. and BioNJ Member Eisai announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to chemotherapy for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. The findings, based on five years of follow-up from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel), for these patients with advanced endometrial carcinoma. In the trial, a total of 827 patients (697 whose cancer was mismatch repair proficient [pMMR] and 130 whose cancer was mismatch repair deficient [dMMR]) were randomized to receive KEYTRUDA plus LENVIMA (n=411) or chemotherapy (n=416).

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients With Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

Rahway-based BioNJ Member Merck & Co. Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck. The median overall survival for advanced ovarian cancer following recurrence can be as little as two years, with a five-year survival rate of 31.8% for those with distant stage disease. Between 70% and 80% of patients diagnosed with advanced ovarian cancer will experience disease progression following standard treatment with platinum-based chemotherapy regimens, highlighting the need for new treatment options.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Rahway-based BioNJ Member Merck & Co. announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. At the first interim analysis, with a median study follow-up of 15.6 months, KEYTRUDA plus chemotherapy with or without bevacizumab (n=322) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the study’s primary endpoint, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.58-0.84]; p<0.0001) in the all comers population of patients with platinum-resistant recurrent ovarian cancer compared to placebo plus chemotherapy with or without bevacizumab (n=321).

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients With Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Rahway-based BioNJ Member Merck & Co. announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. After a median follow-up of 25.6 months, KEYTRUDA plus Padcev, as perioperative treatment, demonstrated a statistically significant and clinically meaningful improvement in EFS, the trial’s primary endpoint, reducing the risk of EFS events by 60% (HR=0.40 [95% CI, 0.28-0.57]; p<0.0001) versus surgery alone in patients with MIBC who are not eligible for or declined cisplatin-based chemotherapy

Merck Announces $10B Acquisition of Verona Pharma

Rahway-based BioNJ Member Merck & Co. announced that it has completed the acquisition of Verona Pharma plc. It is now a wholly owned subsidiary of Merck, and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. With this acquisition, Merck has added Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio. The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years and combines bronchodilator and non-steroidal anti-inflammatory effects.

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

Rahway-based BioNJ Member Merck & Co. announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worsening events by 76% (hazard ratio [HR] 0.24 [95% confidence interval [CI], 0.14 to 0.41]; p<0.0001) as measured by a composite endpoint of all-cause death, the need for non-planned PAH-related hospitalization ≥24 hours, atrial septostomy, lung transplantation or PAH deterioration. HYPERION included participants who were within their first year of diagnosis (median seven months and as early as one month), with over 70% of trial participants on double background therapy.

Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases

Rahway-based BioNJ Member Merck & Co. announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases: MK-7240-12 ( NCT06956235) studying patients with moderate to severe hidradenitis suppurativa(HS); MK-7240-013 ( NCT07133633) studying patients with radiographic axial spondyloarthritis(r-axSpA; also known as ankylosing spondylitis); MK-7240-014 ( NCT07176390) studying patients with rheumatoid arthritis(RA). Global recruitment of these trials has begun, targeting enrollment of more than 640 patients across the three studies. With the initiation of these Phase 2b trials, tulisokibart is now being investigated in a total of six diseases.

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults With Virologically Suppressed HIV-1 Infection

Rahway-based BioNJ Member Merck & Co. announced the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that was virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF (50 mg/200 mg/25 mg)] in trial MK-8591A-052 or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. These additional findings follow positive Phase 3 data , which showed that the investigational two-drug regimen of DOR/ISL maintained viral suppression and demonstrated non-inferiority to the three-drug regimen BIC/FTC/TAF in MK-8591A-052 and baseline ART in MK-8591A-051, with no observed treatment-emergent resistance to DOR or ISL. In trial MK-8591A-052, adults living with virally suppressed HIV-1 infection who switched to DOR/ISL from BIC/FTC/TAF showed minimal changes in weight and body composition at Week 48 (exploratory endpoints).

TECVAYLI® Plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Raritan-based BioNJ Member Johnson & Johnson announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) versus investigator’s choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) who received one to three prior lines of therapy. At almost three years follow-up, the combination of TECVAYLI and DARZALEX FASPRO met the primary endpoint of progression-free survival (PFS) (the time a treatment keeps a patient’s cancer from progressing or death) and the results were statistically significant and superior to standard of care.

Subcutaneous Amivantamab Delivers Promising 45 Percent Overall Response Rate With Median Duration of 7.2 Months in Recurrent or Metastatic Head and Neck Cancer

Raritan-based BioNJ Member Johnson & Johnson announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy. The study used the new subcutaneous formulation of amivantamab, which can be delivered in a five-minute manual injection, offering increased patient convenience compared to intravenous RYBREVANT® (amivantamab-vmjw). Patients with R/M HNSCC have limited options and poor outcomes after disease progression on a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy.2 Many are unable to receive further treatment, and for those who do, response rates with available therapies are typically only 10 to 24 percent.

U.S. FDA Approves SIMPONI® (golimumab) for the Treatment of Pediatric Ulcerative Colitis

New Brunswick-based BioNJ Member Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI® (golimumab) for the treatment of children living with moderately to severely active ulcerative colitis (UC), weighing at least 15 kg. This approval builds on the SIMPONI® indication for adults living with moderately to severely active UC, which together represents more than one million Americans living with this condition. The approval is supported by data from the PURSUIT program, which included two multi-center, open-label studies to evaluate the efficacy, safety, and pharmacokinetics of subcutaneously administered SIMPONI® for the treatment of pediatric UC. In the Phase 3 PURSUIT 2 study, the primary endpoint of clinical remission at Week 6 was achieved by 32% of patients.

Johnson & Johnson to Spin Off Orthopedics Unit as DePuy Synthes

New Brunswick-based BioNJ Member Johnson & Johnson plans to spin off its orthopedics business into a standalone company. The move comes as part of a bid to focus J&J’s medical technology division on faster-growing areas. The New Brunswick-based health giant said the division will separate and form a new company, named DePuy Synthes, within the next 18 to 24 months. According to J&J, the unit’s portfolio of surgical instruments and hip, knee and shoulder replacements, generated around $9.2 billion last year ― about 10% of total revenue. Upon completion of the planned separation, DePuy Synthes would establish the largest, most comprehensive orthopedics-focused company, with leading market share positions across major product categories. J&J said the divestment would enable it to focus on high-growth, high-margin areas, such as oncology, immunology, neuroscience, surgery, vision care and cardiovascular.

Kyowa Kirin and Kura Oncology Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and Flt3 Mutations in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

BioNJ Member Kyowa Kirin, with a site in Princeton, and Kura Oncology announced dosing of the first patient in a cohort of the KOMET-007 clinical trial (NCT05735184). This cohort evaluates ziftomenib, a once-daily, investigational oral menin inhibitor, combined with cytarabine and daunorubicin (7+3) as well as quizartinib, for patients with newly diagnosed acute myeloid leukemia (AML). Despite recent advances, including regulatory approvals of FLT3 inhibitors such as quizartinib, patients with FLT3/NPM1 co-mutations face a high risk of relapse and limited durable treatment options. Ziftomenib is the only menin inhibitor to have received Breakthrough Therapy Designation by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory NPM1-mutated AML. 

Kyowa Kirin and Kura Oncology Announce First Patient Dosed in Pivotal Phase 3 Komet-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

BioNJ Member Kyowa Kirin, with a site in Princeton, and Kura Oncology announced that the first patient has been dosed under the KOMET-017 clinical trial protocol (NCT07007312), comprising two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib, Kura Oncology’s investigational menin inhibitor, in combination with both intensive and nonintensive combination regimens in patients with newly diagnosed NPM1-mutant (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Each frontline trial design includes dual-primary endpoints to support potential U.S. accelerated approval and full approval. The trial is intended to serve as a registrational study and builds on encouraging clinical data previously reported with ziftomenib in genetically defined subsets of AML. The trial is expected to enroll patients at up to 200 sites worldwide, reflecting strong global interest in advancing ziftomenib for patients in need.

Lilly's Verzenio® (abemaciclib) Prolonged Survival in HR+, HER2-, High-Risk Early Breast Cancer With Two Years of Treatment

BioNJ Member Eli Lilly and Company, with a site in Branchburg, announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. The data presented include results from the primary OS analysis reflecting a median follow-up of 6.3 years, with more than 75% of patients having been followed for at least four years after completion of the two-year Verzenio treatment period.

Lilly's Omvoh (Mirikizumab-Mrkz) is the First and Only IL-23p19 Antagonist to Show Four Years of Sustained, Corticosteroid-Free Comprehensive Patient Outcomes in Ulcerative Colitis

New data from BioNJ Member Eli Lilly and Company, with a site in Branchburg, showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC) achieve sustained, long-term outcomes through four years. The results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy (27%). These data are the final results from the LUCENT-3 Phase 3 open-label extension study. The long-term safety profile in patients with moderately to severely active UC was consistent with the known safety profile of Omvoh with no new safety signals observed. 

Lilly's Oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Reconfirming Its Potential as a Foundational Treatment in Type 2 Diabetes

BioNJ Member Eli Lilly and Company, with a site in Branchburg, announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin. Separately, ACHIEVE-5 assessed orforglipron versus placebo in adults with type 2 diabetes and inadequate glycemic control with titrated insulin glargine, with or without metformin and/or SGLT-2 inhibitors. In both trials, orforglipron (3 mg, 12 mg, 36 mg) met the primary and all key secondary endpoints at 40 weeks for both the efficacy and treatment-regimen estimands, delivering significant A1C reduction and weight loss as well as improvements in multiple cardiovascular risk factors, all consistent with previously disclosed studies in type 2 diabetes.

Palisades Therapeutics Demonstrates Breakthrough Anti-Metastatic Activity in Advanced Prostate Cancer Models

Cliffside Park-based Pop Test Oncology LLC, operating as Palisades Therapeutics, announced compelling pre-clinical results for investigational compounds Phase 2- PT150 and Pre-clinical Dimer-PT157, demonstrating potent anti-metastatic activity in AR/GR-driven prostate cancer models using the revolutionary Zebrafish Tumor Xenograft (ZTX® ONCOLEADS) Platform. The breakthrough findings, generated through a global collaboration with BioReperia AB (Sweden), Department of Urology at the Icahn School of Medicine at Mount Sinai, and leading research institutions, show that these novel therapeutics significantly outperform existing treatments in preventing cancer metastasis — the primary cause of prostate cancer mortality. PT150 delivered marked reduction in metastatic dissemination of LNCaP prostate cancer cells as a single agent, demonstrating potent stand-alone anti-metastatic efficacy that surpassed standard-of-care treatments.

Research on Work Productivity Among Japanese Workers Published in the Journal of Occupational Health — Visualizing the Impact of a Range of Diseases on Productivity Using Large-Scale Data

BioNJ Member, Otsuka Pharmaceutical Co., Ltd., with a site in Princeton, announced that the results of a joint study on work productivity by disease among Japanese workers have been published in the academic journal Journal of Occupational Health, issued by the Japan Society for Occupational Health. The study, titled “Work productivity by diseases diagnosed among workers: a study using large-scale claims data and survey data of workers in Japan”, was conducted jointly by Otsuka and DeSC Healthcare Inc. The aim was to clarify the actual state of productivity loss due to various diseases among Japanese workers and to estimate the cost of such losses.

N.J. Dominates Culture List: J&J, Merck and More Ranked on Forbes’ Best Employers for Company Culture

A new national ranking highlights the organizations that have successfully fostered a strong, unified company culture, and New Jersey-based companies are prominently featured. Forbes has released its inaugural ranking of America’s Best Employers for Company Culture, identifying 600 companies nationwide that inspire a deep sense of purpose and loyalty among their employees. The ranking is based on an independent survey conducted by Forbes and market research firm Statista. More than 218,000 workers at companies with at least 1,000 employees were surveyed anonymously. Eighteen New Jersey-headquartered companies earned a spot on the 600-company list, with several achieving top national rankings, including BioNJ Member Johnson & Johnson at rank 13.

Citius Oncology and EVERSANA Sign Exclusive Agreement for Q4 2025 Launch of LYMPHIR

Cranford-based Citius Oncology, Inc. announced it has signed an exclusive agreement with EVERSANA, a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR, Citius Oncology’s FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy. The U.S. Food and Drug Administration approved LYMPHIR in August 2024 and is the only systemic treatment for CTCL that targets the IL-2 receptor on malignant T-cells and T-regs. Under the master service agreement, EVERSANA will serve as Citius Oncology’s exclusive commercialization partner, providing an integrated suite of pre- and post-launch operation services. These services include medical information, pharmacovigilance, revenue cycle management, data and analytics, program management and channel management.

Citius Oncology Signs U.S. Distribution Agreement With McKesson to Support LYMPHIR™ Commercial Launch

Cranford-based Citius Oncology, Inc. announced it has entered into a distribution services agreement with McKesson Corporation one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The agreement with McKesson completes Citius Oncology's core U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone ensures broad and reliable access to the therapy in preparation for its planned commercial launch in the fourth quarter of 2025.

Hikma and Celltrion Strengthen Partnership to Expand Biosimilar Access in MENA

Berkely Heights-based Hikma Pharmaceuticals PLC, and its long-standing partner Celltrion Inc., have signed exclusive licensing agreements across the Middle East and North Africa region. The new agreements will broaden access to cutting-edge and affordable biologics through the introduction of six biosimilar treatments to the region. This also marks a significant advancement in expanding access to biosimilar treatments across key therapeutic areas, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases and oncology. By offering high-quality, cost-effective alternatives to complex biologics, Hikma is enabling broader patient access to life-saving and life enhancing therapies that were previously restricted due to high costs or limited availability. Under the agreements, Hikma will hold exclusive commercialization rights across all MENA markets, while Celltrion will be responsible for the development, manufacturing and supply of the treatments.

NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human

MetasTx announced progress on its two-part precision oncology platform designed to identify and treat men with prostate cancer who are most likely to progress to lethal metastasis. The company’s companion diagnostic is in proof-of-concept, supported by a National Cancer Institute Small Business Innovation Research award, and its next-generation KIT inhibitor program is targeting first-in-human evaluation on an accelerated, capital-efficient timeline. The platform pairs a practical diagnostic to find the right patients on Day 1 with a targeted therapy aimed upstream of the cancer cell’s signals to spread. Most of the 299,000 U.S. men diagnosed with prostate cancer in 2024 and on active surveillance know it is the hard-to-detect who will silently progress. MetasTx’s integrated approach enables physicians to select, and treat, the high-risk subset earlier, aligning with value-based care priorities across New Jersey’s hospital and payer ecosystem.

AI/Digital Health

Made Scientific and Streamline Bio Collaborate to Bring AI-driven Robotics to Cell Therapy Manufacturing

Princeton-based BioNJ Member Made Scientific and Streamline Bio, a next-generation autonomous robotics company, announced a collaboration to accelerate the use of AI-driven precision robotics in cell therapy manufacturing. The companies completed the initial validation of Streamline Bio’s robotics platform in a live cell therapy production environment at Made Scientific’s Princeton facility, paving the way for the integration of the fully robotic solution into Good Manufacturing Practice (GMP) cleanrooms for commercial-scale use. The automation of manual, labor-intensive steps is expected to reduce operator burden, mitigate human error and decrease overall costs, allowing skilled personnel to focus on higher-value activities. Furthermore, the platform’s digital-first design enables full data traceability.

Made Scientific and Syenex Partner to Revolutionize T Cell Therapy Manufacturing With Next-Gen Bioengineering

Princeton-based BioNJ Member Made Scientific and synthetic biology company, Syenex, announced a technology partnership aimed at dramatically improving the scalability and efficiency of engineered T cell therapies. The collaboration integrates Syenex’s proprietary UltraCell™ and RapidCell™ bioengineering systems into Made Scientific’s manufacturing processes. This partnership is designed to tackle the critical challenges of cost and scalability inherent in traditional lentiviral- and retroviral-vector-engineered T cell therapy manufacturing. Syenex’s advanced delivery vector engineering systems offer significant advantages, including up to 10x improvement in gene delivery efficiency and the potential for vastly reduced manufacturing timelines and substantially lower costs. Initial proof-of-concept studies have already demonstrated the strength of the collaboration. In their first joint study, Made and Syenex found that the RapidCell™ system provides a suitable, more efficient and cost-effective alternative to commonly used cell transduction and activation reagents.

CoreWeave and Poolside Forge Alliance to Accelerate AI Cloud Services and AGI

Livingston-based BioNJ Member CoreWeave announced a significant new partnership with Poolside, a foundation model company focused on building artificial general intelligence (AGI). The collaboration is designed to provide Poolside with the extreme computing power necessary to train multi-trillion parameter models and deploy AI agents across the enterprise. Under the agreement, CoreWeave will immediately supply Poolside with a state-of-the-art cluster of NVIDIA GB300 NVL72 systems, which includes more than 40,000 GPUs. Beyond the initial cluster, CoreWeave will play a crucial role in Poolside’s long-term infrastructure strategy by providing its cloud solutions for Project Horizon. CoreWeave is slated to serve as the anchor tenant and operational partner for the first phase of the project, which encompasses 250MW of gross power, with an option to expand capacity by an additional 500MW.

CoreWeave Acquires Monolith AI to Inject AI-Driven Robotics into Industrial Manufacturing

Livingston-based BioNJ Member CoreWeave announced a definitive agreement to acquire Monolith AI Limited. This acquisition is set to expand CoreWeave’s full-stack AI cloud platform deep into the industrial sector, targeting companies in manufacturing, automotive and aerospace. The combination of Monolith’s simulation and test-driven machine learning capabilities with CoreWeave’s powerful AI cloud infrastructure aims to dramatically shorten R&D cycles and accelerate product development for enterprise clients. Monolith’s platform is already utilized by major engineering companies, including Nissan, BMW, and Honeywell, to cut months out of the product development timeline. The company is recognized for its expertise in embedding machine learning directly into engineering workflows. By automating decision-making and improving reliability, the technology significantly reduces the need for expensive and time-consuming physical testing that has traditionally slowed industrial progress.

Kenvue Partners With Albert Invent to Boost End-to-end R&D Efforts With AI

Albert Invent, a frontier AI company, announced a strategic partnership with Summit-based Kenvue Inc., maker of consumer health products like Zyrtec, Neutrogena and Listerine, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize and accelerate the end-to-end product lifecycle by leveraging Albert Invent’s foundational AI models. The companies began working together in Q1 2025, as part of a multiyear partnership set to drive value for scientists by streamlining hundreds of R&D processes and methodologies around the world. The partnership aims to augment and accelerate the work of Kenvue’s global team of scientists with Albert Invent’s end-to-end AI platform, to simplify processes to gain efficiencies both inside and outside of the lab and allow its scientists to meet evolving consumer needs with even greater impact.

BD Launches New AI-Enabled Solutions for Connectivity Across Health Care Settings

BD recently launched the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. 

Built on Amazon Web Services’ (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform leverages the latest in AI technologies, such as natural language search in analytics, and is scalable to meet the data volumes created by nearly three million smart connected BD devices. With Analytics in the BD Incada™ Platform, data from BD’s leading medication management solutions now flows through a secure, cloud platform. The stackable device configuration offers more medication storage capacity to improve medication availability from refrigerated to ambient storage. 

Made Scientific and Streamline Bio Collaborate to Bring AI-driven Robotics to Cell Therapy Manufacturing

Princeton-based BioNJ Member Made Scientific and Streamline Bio, a next-generation autonomous robotics company, announced a collaboration to accelerate the use of AI-driven precision robotics in cell therapy manufacturing. The companies completed the initial validation of Streamline Bio’s robotics platform in a live cell therapy production environment at Made Scientific’s Princeton facility, paving the way for the integration of the fully robotic solution into Good Manufacturing Practice (GMP) cleanrooms for commercial-scale use. The automation of manual, labor-intensive steps is expected to reduce operator burden, mitigate human error and decrease overall costs, allowing skilled personnel to focus on higher-value activities. Furthermore, the platform’s digital-first design enables full data traceability.

Made Scientific and Syenex Partner to Revolutionize T Cell Therapy Manufacturing With Next-Gen Bioengineering

Princeton-based BioNJ Member Made Scientific and synthetic biology company, Syenex, announced a technology partnership aimed at dramatically improving the scalability and efficiency of engineered T cell therapies. The collaboration integrates Syenex’s proprietary UltraCell™ and RapidCell™ bioengineering systems into Made Scientific’s manufacturing processes. This partnership is designed to tackle the critical challenges of cost and scalability inherent in traditional lentiviral- and retroviral-vector-engineered T cell therapy manufacturing. Syenex’s advanced delivery vector engineering systems offer significant advantages, including up to 10x improvement in gene delivery efficiency and the potential for vastly reduced manufacturing timelines and substantially lower costs. Initial proof-of-concept studies have already demonstrated the strength of the collaboration. In their first joint study, Made and Syenex found that the RapidCell™ system provides a suitable, more efficient and cost-effective alternative to commonly used cell transduction and activation reagents.

CoreWeave and Poolside Forge Alliance to Accelerate AI Cloud Services and AGI

Livingston-based BioNJ Member CoreWeave announced a significant new partnership with Poolside, a foundation model company focused on building artificial general intelligence (AGI). The collaboration is designed to provide Poolside with the extreme computing power necessary to train multi-trillion parameter models and deploy AI agents across the enterprise. Under the agreement, CoreWeave will immediately supply Poolside with a state-of-the-art cluster of NVIDIA GB300 NVL72 systems, which includes more than 40,000 GPUs. Beyond the initial cluster, CoreWeave will play a crucial role in Poolside’s long-term infrastructure strategy by providing its cloud solutions for Project Horizon. CoreWeave is slated to serve as the anchor tenant and operational partner for the first phase of the project, which encompasses 250MW of gross power, with an option to expand capacity by an additional 500MW.

CoreWeave Acquires Monolith AI to Inject AI-Driven Robotics into Industrial Manufacturing

Livingston-based BioNJ Member CoreWeave announced a definitive agreement to acquire Monolith AI Limited. This acquisition is set to expand CoreWeave’s full-stack AI cloud platform deep into the industrial sector, targeting companies in manufacturing, automotive and aerospace. The combination of Monolith’s simulation and test-driven machine learning capabilities with CoreWeave’s powerful AI cloud infrastructure aims to dramatically shorten R&D cycles and accelerate product development for enterprise clients. Monolith’s platform is already utilized by major engineering companies, including Nissan, BMW, and Honeywell, to cut months out of the product development timeline. The company is recognized for its expertise in embedding machine learning directly into engineering workflows. By automating decision-making and improving reliability, the technology significantly reduces the need for expensive and time-consuming physical testing that has traditionally slowed industrial progress.

Kenvue Partners With Albert Invent to Boost End-to-end R&D Efforts With AI

Albert Invent, a frontier AI company, announced a strategic partnership with Summit-based Kenvue Inc., maker of consumer health products like Zyrtec, Neutrogena and Listerine, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize and accelerate the end-to-end product lifecycle by leveraging Albert Invent’s foundational AI models. The companies began working together in Q1 2025, as part of a multiyear partnership set to drive value for scientists by streamlining hundreds of R&D processes and methodologies around the world. The partnership aims to augment and accelerate the work of Kenvue’s global team of scientists with Albert Invent’s end-to-end AI platform, to simplify processes to gain efficiencies both inside and outside of the lab and allow its scientists to meet evolving consumer needs with even greater impact.

People in the News

e453cbae-cd0c-439a-bfdc-f099d47061ee image

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Florham Park-based BioNJ Member Phathom Pharmaceuticals announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. Sanjeev Narula most recently served as Chief Financial Officer at Intra-Cellular Therapies, where he oversaw finance leading up to its $14.6 billion acquisition by Johnson & Johnson and played a key role in capital strategy, M&A and financial planning. He previously served as CFO of Viatris and CFO of Upjohn, a former Pfizer division, where he gained extensive global experience across commercial, R&D, Information Technology and global supply functions. During his 16 years at Pfizer, he held senior finance roles, including CFO for Pfizer’s Essential Health Business and CFO of the Primary Care Business Unit.

CoreWeave Taps Former Amazon Executive Jon Jones as First Chief Revenue Officer to Drive Hypergrowth in AI Cloud

BioNJ Member CoreWeave announced the appointment of Jon Jones as its first-ever Chief Revenue Officer. Mr. Jones will lead the company’s global revenue organization, focusing on scaling products and sales to meet the demand of the rapidly growing AI industry. Mr. Jones, a recognized AI industry leader and Silicon Valley native, brings over two decades of leadership experience through major periods of business expansion and transformation. He joins Livingston-based CoreWeave from Amazon, where he most recently served as global head of startups and venture capital and previously as vice president of Go-to-Market, Products & Services, focusing on AI innovation and cloud adoption. Mr. Jones will work alongside Max Hjelm, who previously built the company’s strong Go-To-Market team and helped propel CoreWeave to its current market position as “The Essential Cloud for AI.”

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Princeton-based BioNJ Member Soligenix announced the update of its United States (U.S.) Medical Advisory Board (MAB) for cutaneous T-cell lymphoma (CTCL) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of HyBryte™ (synthetic hypericin) for the treatment of CTCL, a rare class of non-Hodgkin's lymphoma (NHL). Comprised of dermatologic and oncologic thought leaders with extensive experience in CTCL, the MAB has played an important advisory role in the conduct of the ongoing FLASH2 Phase 3, pivotal clinical study and will continue to contribute to the program as we advance development activities including worldwide regulatory interactions with health authorities.

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Princeton-based BioNJ Member Soligenix announced the expansion of its European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early stage disease. This confirmatory, 18-week study is expected to enroll approximately 80 patients and is targeted to report top-line results in the second half of 2026. Comprised of internationally renowned physicians with extensive experience in treating and running clinical research trials in CTCL, this esteemed expanded MAB will play an important advisory role in the conduct and interpretation of the upcoming Phase 3 clinical study and the associated regulatory interactions with health authorities.

Tonix Pharmaceuticals Taps Former Bayer and Hutchmed Executive Ganesh Kamath to Oversee Market Access

Ganesh Kamath has recently been named Head of Market Access for Tonix Pharmaceuticals. Tonix is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates based in Chatham. Mr. Kamath worked at CuriaGlobal, serving as VP of FP&A, business development and sales operations. He aimed at strengthening business development and operational performance. Prior to that, he was SVP and chief financial officer at Hutchmed International, where he established pricing governance frameworks and advanced market access strategies. Earlier in his career, Mr. Kamath held senior leadership roles at Bayer HealthCare within finance and market access, overseeing strategic pricing, contracting, reimbursement and gross to net management across a portfolio of more than 25 brands. 

Academia/Institutions/Incubators

5760b1d5-8799-4132-a333-0490b441aa75 image

Students 2 Science Opens Apollo Technology Center in Whippany, Set to Serve Over 100K Students Annually

Students 2 Science (S2S), a Whippany-based STEM (science, technology, engineering and mathematics) nonprofit, has officially opened the Apollo Technology Center at One Apollo Drive in Whippany. The grand opening celebration was attended by industry leaders, foundations, and community partners, with the first students welcomed just days later for a full day of hands-on STEM learning. The new facility is designed to significantly expand access to cutting-edge science and technology education across the state, providing students with hands-on experience using the kind of state-of-the-art laboratory instrumentation found in professional settings. “This venture was a community effort,” said Paul Winslow, president and co-founder of Students 2 Science. “The S2S community of champions came together… We look forward to serving over 100,000 students annually.”

Mercer County Community College Launches Biomanufacturing Program, Unveils Aseptic Mobile Laboratory

Mercer County Community College (MCCC), with support from Johnson & Johnson, the MCCC Foundation and NJBioFutures, announced the launch of the college’s Aseptic Biomanufacturing Program and Aseptic Mobile Laboratory. Dr. Deborah E. Preston, MCCC President, was joined by representatives of Johnson & Johnson, NJBioFutures and public officials for a ribbon-cutting ceremony and tour of the 30-foot clean lab trailer, now housed at MCCC’s James Kerney Campus in Trenton. The anticipated program begins this fall. MCCC students may enroll year-round, online through the college’s Workforce Training website and select program options that best fit their goals, including good manufacturing practice professional; pharmaceutical aseptic cleaning; aseptic biomanufacturing.

Coriell Breaks Ground on New Life Sciences Campus in Camden

A major life sciences and innovation project took its next step in Camden for Coriell Institute for Medical Research. The four-story building will serve as the Coriell Institute’s new headquarters, research center and biorepository. It will also house six National Institutes of Health (NIH) biobanks. The NJ Coriell Labs Innovation Center will occupy the top two floors. It will feature 45,000 square feet of premium incubator space to host biotechnology companies. The NJEDA is investing $20 million and Coriell Institute $21 million for the project. The site is slated to open in early 2028 and create 100 permanent jobs. “The launch of our Strategic Innovation Centers program holds tremendous promise to fuel discovery, accelerate breakthroughs and drive economic growth,” said Gov. Phil Murphy, who was on-hand for the groundbreaking.

Kean University Researcher Conducts Study on Osteoarthritis’ Impact on the Brain

Kean University Assistant Professor Alka Bishnoi has published research on the link between balance and cognition in women with osteoarthritis (OA), suggesting the disease may reduce the brain’s ability to react to challenging balance tasks. OA is a degenerative joint disease that leads to pain, stiffness, and swelling in the affected joint. The research project began in 2019 when Bishnoi was studying for her doctorate at the University of Illinois at Urbana-Champaign and working with a team of researchers collecting data for a larger project on OA. The balance tests were conducted at the Mobility and Fall Prevention Research Laboratory at UIUC. A member of the faculty at Kean for three years, Bishnoi focuses her research on the aging population.

New Rowan University Lab Is Super-Powered to Advance Manufacturing Through AI

The rapid development of artificial intelligence and the usability of large language models have promised to transform industries on a large scale, but first engineers must figure out how to integrate intelligent systems with real-world manufacturing methods. To accomplish that goal, Rowan University’s Digital Engineering Hub (DEHub) is merging smart technology with advanced manufacturing methods through its well-equipped lab launched this fall. Housed at Henry M. Rowan College of Engineering’s Rowan Hall and directed by Antonios Kontsos, Ph.D., the DEHub lab is capable of digitizing real-world objects, as well as creating new objects based on human- or machine-engineered designs. The lab features 3D polymer and metal printers, 3D scanners for digitizing existing objects and devices for mechanical sensing and testing.

Princeton Alumna Wins 2025 Nobel Prize in Medicine for Immune Tolerance Discovery

Princeton University Alumna Mary Brunkow was awarded the 2025 Nobel Prize in Medicine. Along with Fred Ramsdell and Shimon Sakaguchi, Dr. Brunkow was awarded for discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body. “Peripheral immune tolerance” refers to a subtle but vital component of the human immune system. This is a piece that balances the body’s need to fight off external threats without attacking internal systems. It was once thought that this balance was achieved through “central immune tolerance,” in which new T cells that could attack the host are weeded out in the thymus before they are unleashed upon the body. However, the trio added a new layer to this theory.

Inspira Health Hospitals Earn ACC Accreditations for Heart Failure and Cardiac Cath Lab Excellence

Inspira Health announced a major achievement in its commitment to high-quality cardiac care, with Inspira Medical Centers Mullica Hill, Vineland and Elmer all earning the American College of Cardiology’s (ACC) prestigious Heart Failure accreditation. The recognition is awarded for top-tier cardiac care and consistent improvements in heart failure patient outcomes. In a related announcement, Inspira’s Cardiac Cath Labs also achieved the ACC Cardiac Cath Lab accreditation for their dedication to safe, efficient, and patient-centered cardiac catheterization procedures. These achievements underscore Inspira’s commitment to clinical excellence and advancing processes in cardiovascular care, especially as one of only two health systems in southern New Jersey to receive the ACC Heart Failure designation. This distinction emphasizes the organization’s mission to bridge rural health care gaps, following earlier national recognition for heart failure excellence from the American Heart Association.

Industry Events

calendar-white.png

Community Colleges, NJBIA to Report Out on Career Pathways Projects

The State’s community colleges and NJBIA have scheduled a series of online presentations that will update the public on the progress of various Pathways to Career Opportunities initiatives related to rapidly growing industries where highly skilled workers are in-demand. Leaders in business, industry, labor unions, workforce development boards, county vocational-technical schools, colleges and universities and community-based organizations are urged to participate in these collaborative meetings to gain insights into work that’s shaping the future of the workforce in these five sectors: Manufacturing & Supply Chain Management; Technology & Innovation; Health Services; Infrastructure & Energy; and Emerging Industries.  

Luminaries in Healthcare Leadership Featuring Robert A. Harrington, M.D.

October 29, 2025 | Cornell University

The Luminaries in Healthcare Leadership series invites senior industry leaders to share their perspectives on cutting-edge issues related to the rapidly evolving healthcare industry. We are excited to welcome Robert A. Harrington, MD, Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs at Cornell University. Join us for a fireside chat from 6:30 p.m.-7:30 p.m., moderated by Rainu Kaushal, MD, MPH, Senior Associate Dean for Health Data Sciences and Chair of Population Health Sciences at Weill Cornell Medicine. Reception to follow from 7:30 p.m.-8:00 p.m.

2025 Female Founded Conference

November 15, 2025 | Hosted by Princeton University

This year’s conference celebrates the powerful intersection of innovation, entrepreneurship, and wellbeing — spotlighting female-founded companies that are redefining the future of healthcare. From cutting-edge wearables and digital health platforms to groundbreaking solutions in mental health and wellness, we’re showcasing a dynamic range of ventures improving lives across the health spectrum. While many of these companies focus on women’s health, the innovations represented span all areas of healthcare and wellbeing, driven by founders who are breaking barriers and building a healthier future for all.

Executive MBA/MS in Healthcare Leadership Westchester Networking Event

November 19, 2025 | Hosted by Cornell Executive MBA/MS in Healthcare Leadership Program

Join Cornell's Executive MBA/MS in Healthcare Leadership program on Wednesday, November 19 at Hudson Grille in White Plains for an engaging, hands-on networking session focused on crafting an impactful 60-second pitch. This session will feature Nicole Woodward, Senior Associate Director from the Career Development Office for Cornell's Executive MBA Programs. Guests will also have the opportunity to connect with prospective candidates, admissions representatives, and accomplished alumni to learn how Cornell's EMBA/MS in Healthcare Leadership can accelerate your career while building meaningful connections.

Doing Business in Eurasia

Throughout Spring 2025 - Fall 2026 | Hosted by Mid-Atlantic - Eurasia Business Council

Mid-Atlantic - Eurasia Business Council is pleased to invite you to its Doing Business in Eurasia seminar series that will be taking place throughout Spring 2025 - Fall 2026. The upcoming seminars organized by the Mid-Atlantic - Eurasia Business Council will be held in Philadelphia, PA; Harrisburg, PA; Wilmington, DE; Pittsburgh, PA; New York, NY; Allentown, PA; Baltimore, MD; and Princeton, NJ. The Doing Business in Eurasia seminar series addresses emerging business opportunities for foreign companies and discusses the legal and regulatory environment in Eurasian countries, including Central Asia, Eastern Europe and European Union.

Students 2 Science STEM Volunteer Opportunities

Inspire the next generation of STEM leaders – Volunteer at Students 2 Science (S2S), a recognized leader in providing rigorous, hands-on STEM experiences for students in 5th-12th grades. S2S is currently recruiting volunteers for its in-lab ISAAC program, which offers rigorous, hands-on STEM experiences for middle and high school students in state-of-the-art laboratories in East Hanover and Newark, NJ. For more information, click here. To register to volunteer with S2S or if you have any questions, please email info@students2science.org or call (973) 947-4880 ext. 545.

Partner Spotlight


 

Please contact BioNJ with any questions.

BioNJ@BioNJ.org  | 609-890-3185 | www.BioNJ.org

Follow us on:

LinkedIn  X  Facebook  Instagram

This e-newsletter was sent by BioNJ.